<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345901</url>
  </required_header>
  <id_info>
    <org_study_id>DRCR.net Protocol AD</org_study_id>
    <nct_id>NCT03345901</nct_id>
  </id_info>
  <brief_title>PROMINENT-Eye Ancillary Study (Protocol AD)</brief_title>
  <official_title>PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite improved glycemic and systemic control for many patients with diabetes, over the past
      several decades, diabetic retinopathy (DR) develops and progresses in a large proportion of
      patients, and visual loss from diabetic eye complications continues to be a leading cause of
      blindness in the US and other developed countries worldwide. Thus, even a modest ability to
      prevent DR onset or to slow DR worsening might substantially reduce the number of patients at
      risk for diabetes-related vision loss worldwide. Widespread use of an oral agent effective at
      reducing worsening of DR might also decrease the numbers of patients who undergo treatment
      for DR and diabetic macular edema (DME) and who are consequently at risk for side effects
      that adversely affect visual function. Two major studies of fenofibrate, the Fenofibrate
      Intervention and Event Lowering in Diabetes (FIELD) and The Action to Control Cardiovascular
      Risk in Diabetes (ACCORD)-eye study, have demonstrated clinically important reduction in
      progression of retinopathy in patients with diabetes assigned to fibrate compared with
      placebo. However, despite the positive clinical trial results, fenofibrate has not gained
      wide acceptance as a preventive agent by either ophthalmologists or primary diabetes care
      providers. Thus, it is important to provide further evidence demonstrating whether or not
      selectively increasing peroxisome proliferator-activated receptor alpha (PPARα) activity
      reduces progression of retinopathy in patients with diabetes and non-proliferative diabetic
      retinopathy at baseline. Pemafibrate is a more potent and selective PPARα modulator than
      fenofibrate. Its efficacy is currently being evaluated in the Pemafibrate to Reduce
      Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) study
      for prevention of cardiovascular events in patients with type 2 diabetes. Given the large
      study cohort with a substantial proportion likely to have DR and the multi-year duration of
      the PROMINENT trial, this study represents a unique opportunity to assess effects of chronic
      PPARα activation through pemafibrate therapy on DR outcomes.

      Primary Study Objective: To assess whether treatment with pemafibrate (0.2 mg orally BID)
      compared with placebo reduces rates of diabetic retinopathy worsening in adults with type 2
      diabetes and diabetic retinopathy without neovascularization who are participating in the
      parent PROMINENT trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2018</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diabetic retinopathy worsening or diabetic macular edema (DME) development (composite outcome) defined as any of the following:</measure>
    <time_frame>4 years</time_frame>
    <description>For participants with 2 study eyes: 3-step worsening on the Early Treatment Diabetic Retinopathy Study (ETDRS) Retinopathy Severity Scale for Persons at a protocol visit
For participants with 1 study eye: 2-step worsening on the ETDRS Retinopathy Severity Scale for Individual Eyes in the study eye at a protocol visit
Procedure undertaken for treatment of proliferative diabetic retinopathy at any time including pan-retinal photocoagulation (PRP), intravitreous anti-vascular endothelial growth factor (VEGF), or vitrectomy in either study eye
Treatment initiated for treatment of diabetic macular edema (DME) at any time including anti-VEGF, corticosteroids, focal/grid laser, or vitrectomy
Development of central-involved DME on OCT with vision loss at 2 or 4-year visit defined as OCT central subfield thickness above machine and gender specific thresholds with at least a 10% increase in thickness from baseline and visual acuity 20/32 or worse (letter score ≤ 78)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with 3-step diabetic retinopathy worsening on color photos or receiving treatment for proliferative diabetic retinopathy (PDR) in either eye at any time (irrespective of diabetic macular edema (DME) status or treatment)</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with 3-step diabetic retinopathy worsening on color photos</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving treatment for proliferative diabetic retinopathy (PDR) in either eye at any time</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants that develop central-involved diabetic macular edema (DME) on optical coherence tomography (OCT) with vision loss or receive treatment for DME in either eye at any time (irrespective of diabetic retinopathy status or treatment)</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of eyes that develop central-involved diabetic macular edema (DME) on optical coherence tomography (OCT) with vision loss</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants receiving treatment for diabetic macular edema (DME) in either eye at any time</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with at least 1, 2 or 3-line losses in visual acuity in either eye</measure>
    <time_frame>4 Years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes from randomization in alanine aminotransferase</measure>
    <time_frame>4 Years</time_frame>
    <description>Blood test, change measured in units per liter (U/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from randomization in aspartate aminotransferase</measure>
    <time_frame>4 Years</time_frame>
    <description>Blood test, change from randomization measured in units per liter (U/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes from randomization in creatine kinase</measure>
    <time_frame>4 Years</time_frame>
    <description>Blood test, change from randomization measured in units per liter (U/L) or SI Units (mkat/L)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Pemafibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>.2 mg pemafibrate orally BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo pill orally BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemafibrate</intervention_name>
    <description>0.2 mg orally BID - twice daily</description>
    <arm_group_label>Pemafibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally BID - twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Already randomized at US or Canadian sites in the PROMINENT study

          -  Ability to cooperate with dilated ophthalmic examination and imaging procedures

          -  At least one eye meets the following study eye inclusion criteria:

               1. Early Treatment Diabetic Retinopathy Study (ETDRS) Diabetic Retinopathy Severity
                  level between 20 and 53 (minimal to severe non-proliferative diabetic retinopathy
                  (NPDR)), inclusive, on color fundus photographs confirmed by central Reading
                  Center grading.

        Exclusion Criteria:

          -  Study eye exclusion criteria are:

             a. Neovascularization present. b. Current central-involved diabetic macular edema (DME
             based on optical coherence tomography (OCT) central subfield thickness (CST) i. Zeiss
             Cirrus: CST ≥ 290µm in women or ≥ 305µm in men ii. Heidelberg Spectralis: CST ≥ 305µm
             in women or ≥ 320µm in men c. Known major non-diabetic intraocular pathology that in
             the opinion of the investigator would substantially and adversely affect visual acuity
             or lead to ocular neovascularization during the course of the study d. Anticipated
             need for intravitreous anti-vascular endothelial growth factor (VEGF), intravitreous
             corticosteroid, or pan-retinal photocoagulation (PRP) in the next 6 months following
             randomization e. History of intravitreous anti-VEGF or corticosteroid treatment within
             the prior year for any indication.

             f. History of intraocular surgery within prior 4 months or anticipated within the next
             6 months following randomization g. Any history of PRP or vitrectomy h. History of
             yttrium aluminum garnet (YAG) capsulotomy performed within 2 months prior to screening
             i. Aphakia j. Known substantial media opacities that would preclude successful imaging
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Chew, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Eye Institute (NEI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam Glassman, MS</last_name>
    <phone>813-975-8690</phone>
    <email>drcrnet@jaeb.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Retina and Vitreous Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramin Schadlu, MD</last_name>
      <phone>480-999-5458</phone>
      <email>ramin.schadlu@doctrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retinal Diagnostic Center</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amr Dessouki, MD</last_name>
      <phone>408-559-0666</phone>
      <email>amr@dessouki.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macula &amp; Retina Institute</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kent W Small, MD</last_name>
      <phone>818-552-5040</phone>
      <email>kentsmall@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantis Eye Care</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hani Salehi-Had, MD</last_name>
      <phone>714-901-2006</phone>
      <email>h.salehi@atlantiseyecare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Coast Retina Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie L Gasperini, MD</last_name>
      <phone>562-984-7024</phone>
      <email>jgasperinimd@southcoastretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul N Khurana, MD</last_name>
      <phone>650-988-7480</phone>
      <email>RNKHURANA@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Southern California Medical Group, Inc.</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <zip>91361</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenneth R Diddie, MD, FACS</last_name>
      <phone>805-379-0200</phone>
      <email>kdiddie@retinalconsultants-sc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A. T. Ghuman, MD</last_name>
      <phone>239-939-4323</phone>
      <email>TGnori@eye.md</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Retina Consultants</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott M Friedman, MD</last_name>
      <phone>863-682-7474</phone>
      <email>smfriedman83@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Macula Specialists of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary Shienbaum, MD</last_name>
      <phone>305-643-8871</phone>
      <email>Gary.shienbaum@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Retina Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew A Cunningham, MD</last_name>
      <phone>407-849-9621</phone>
      <email>macunning@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeast Eye Institute, P.A. dba Eye Associates of Pinellas</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason M Handza, DO</last_name>
      <phone>727-541-4469</phone>
      <email>jhandza@icloud.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melvin Chen, MD</last_name>
      <phone>941-921-5335</phone>
      <email>srqretina@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center, P.C.</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dennis M Marcus, MD</last_name>
      <phone>706-650-0061</phone>
      <email>dmarcus@southeastretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Eye Group</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul L Kaufman, MD</last_name>
      <phone>404-256-1507</phone>
      <email>paulk@thomaseye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates, S.C.</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew W MacCumber, MD</last_name>
      <phone>708-660-8450</phone>
      <email>macretina@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John-Kenyon American Eye Institute</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard S Lazarus, MD</last_name>
      <phone>800-965-3937</phone>
      <email>hlazarus@johnkenyon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jared S Nielsen, MD</last_name>
      <phone>515-223-8685</phone>
      <email>jnielsen@wolfeclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid-America Retina Consultants, P.A.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William N Rosenthal, MD</last_name>
      <phone>913-663-5900</phone>
      <email>wnrosenthal@midamericaretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Associates, P.A.</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory M Fox, MD</last_name>
      <phone>913-831-7400</phone>
      <email>foxretina@sbcglobal.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina and Vitreous Associates of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas W Stone, MD</last_name>
      <phone>859-263-3900</phone>
      <email>drstone@retinaky.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elman Retina Group, P.A.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J Elman, MD</last_name>
      <phone>410-686-3394</phone>
      <email>elman@elmanretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valley Eye Physicians and Surgeons</name>
      <address>
        <city>Ayer</city>
        <state>Massachusetts</state>
        <zip>01432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisela Velez, MD,MPH,MA</last_name>
      <phone>978-772-4000</phone>
      <email>velezgisela@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chirag P Shah, MD, MPH</last_name>
      <phone>617-367-4800</phone>
      <email>cpshah@eyeboston.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lloyd P Aiello, MD, PhD</last_name>
      <phone>617-309-2520</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis C Glazer, MD, FACS</last_name>
      <phone>616-285-1200</phone>
      <email>glazerlc@vrapc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin J Blinder, MD</last_name>
      <phone>314-367-1181</phone>
      <email>kjblinder@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Western New York</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian P Connolly, MD</last_name>
      <phone>585-442-3411</phone>
      <email>bconnolly@retinaassociatesofwny.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Surgeons of Central New York, PC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G R Hampton, MD</last_name>
      <phone>315-445-8166</phone>
      <email>bhampton@twcny.rr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Carolina Clinical Research, LLC</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cameron M Stone, MD</last_name>
      <phone>828-255-8008</phone>
      <email>stone_study@aea1961.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose and Throat Assoc., PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Browning, MD, PhD</last_name>
      <phone>704-295-3390</phone>
      <email>dbrowning@ceenta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Center</name>
      <address>
        <city>Edmond</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep N Shah, MD</last_name>
      <phone>405-607-6699</phone>
      <email>shah@rvcoklahoma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Consultants</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl R Olsen, MD</last_name>
      <phone>412-683-5300</phone>
      <email>olsenkarl@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard I Breazeale, MD</last_name>
      <phone>423-756-1002</phone>
      <email>amrider@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates, P.C.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M Googe, Jr., MD</last_name>
      <phone>865-588-0811</phone>
      <email>CTgooge@seretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chirag D Jhaveri, MD</last_name>
      <phone>512-279-1252</phone>
      <email>cjhaveri@e-retina.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Center of Texas</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jawad A Qureshi, MD</last_name>
      <phone>817-865-6800</phone>
      <email>jaq@retinacentertx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles C Wykoff, MD, PhD</last_name>
      <phone>713-524-3434</phone>
      <email>ccwmd@houstonretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Calvin E Mein, MD</last_name>
      <phone>210-615-1311</phone>
      <email>cemein@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pemafibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data related to the eye ancillary study will be made available after completion of the study and publication of the outcome manuscript.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

